UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009982 |
|---|---|
| Receipt number | R000011693 |
| Scientific Title | Vitreous concentration of brimonidine tartrate 0.1% topical applied for neuroprotection |
| Date of disclosure of the study information | 2013/02/10 |
| Last modified on | 2017/07/09 09:21:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Vitreous concentration of brimonidine tartrate 0.1% topical applied for neuroprotection
Acronym
Vitreous concentration of topical applied brimonidine tartrate 0.1%
Scientific Title
Vitreous concentration of brimonidine tartrate 0.1% topical applied for neuroprotection
Scientific Title:Acronym
Vitreous concentration of topical applied brimonidine tartrate 0.1%
Region
| Japan |
Condition
Condition
Patients undergo vitrectomy for macular hole or idiopathic epiretinal membrane
Classification by specialty
| Ophthalmology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To determine the vitreous and aqueous humore concentration of brimonidine after topical administration of 0.1% Aiphagan.
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The concentration of brimonidine in human vitreous and aqueous humore.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
topical application of 0.1% brimonidine tartrate
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patient whose age is 20 years old or more when agreement is acquired.
Patient who obtained agreement after enough explanation when participating in this study is received.
Patients diagnosed with macular hole or idiopathic epiretinal membrane.
Key exclusion criteria
History of ocular surgery and inflammation.
Patient who is judged inappropriate for study.
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshihiro Takamura |
Organization
University of Fukui, Faculty of medicine
Division name
Ophthalmology
Zip code
Address
23-3 Shimoaiduki Matsuoka Yoshida Fukui
TEL
0776-61-8403
ytakamura@hotmail.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yoshihiro Takamura |
Organization
University of Fukui, Faculty of medicine
Division name
Ophthalmology
Zip code
Address
23-3 Shimoaiduki Matsuoka Eiheiji Yoshida Fukui
TEL
0776-61-8403
Homepage URL
ytakamura@hotmail.com
Sponsor or person
Institute
Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui
Institute
Department
Personal name
Funding Source
Organization
Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Senju pharmaceutical CO. LTD
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 02 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 11 | Month | 19 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 02 | Month | 10 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 02 | Month | 06 | Day |
Last modified on
| 2017 | Year | 07 | Month | 09 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011693
